Fig. 1

Cisplatin augmented CSC-enriched side-population (SP) and PIK3CA expression in resistant cells. A&B. SP of A2780-CisR represented as FACs dot plot with (a) and without (b) verapamil. c Quantification of SP in A2780-CisR, TOV21G and SKOV3 cells pre and post cisplatin treatment (n = 3). d qPCR analysis demonstrated cisplatin mediated escalation of PIK3CA expression only in main (MP) and SP but not in non-SP (NSP) of A2780-CisR (n = 3). e Cisplatin could induce PIK3CA expression only in resistant (A2780-CisR, SKOV3 and TOV21G),cells while it suppressed PIK3CA expression in sensitive cells (A2780 and OAW42) (n = 3). f Schematic of the full-length PIK3CA promoter and subsequent deletion constructs. g Cisplatin treatment augmented promoter activity of only OS4-PIK3CA construct but not OS1, 2 & 3 in A2780-CisR cells. Data were represented as average ± SEM of at least three independent replicates along with their p-value for statistical significance. (ns-non significant) Also see Additional file 2: Figure S1